Bristol Myers joins in vivo CAR-T race with $1.5B Orbital acquisition

Bris­tol My­ers Squibb is delv­ing fur­ther in­to cell ther­a­pies with the $1.5 bil­lion cash pur­chase of Or­bital Ther­a­peu­tics, the New Jer­sey phar­ma

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.